To,
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Date: 14/11/2026

Scrip Code: 544759, Scrip ID: GLPL,

Subject: Submission of Statement of Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("SEBI Listing Regulations") for the half year ended 30th September 2026.

Sir / Ma'am,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer ('IPO') of the Company during the half year ended September 30, 2026, as mentioned in the object clause of the Prospectus of the Company.

Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their meetings held on November 14, 2026.

We also wish to inform that as the IPO proceeds have been utilized for the purpose stated in the Company's prospectus and there was no deviation in utilization of such funds.

Kindly take the same on your record.

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi

Digitally signed by Ruchi Sanket Modi
Date: 2026.11.14 19:51:15 +05'30'

Ruchi Sanket Modi
Company Secretary cum Compliance Officer

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	Goldline Pharmaceutical Limited
Mode of Fund Raising	Public Issue - Initial Public Offer ('IPO')
Date of Raising Funds	May 19, 2026
Amount Raised	INR 10,06,00,000/-
Report filed for Quarter ended	September 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	NA
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	The Audit Committee has reviewed that there was no deviation/variation in the use of funds raised through Preferential Issue.
Comments of the auditors, if any	NIL

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	**Modified Object, if any**	**Original Allocation (in Lakhs)**	**Modified Allocation, if any**	**Funds Utilised (in Lakhs)**	**Amount of Deviation/Variation for the quarter according to applicable object**	**Remarks if Any**
1. Repayment of all or a portion of certain outstanding	Not Applicable	INR 835.45/-	NIL/ NA	INR 835.45/-	Not Applicable	-

2. General corporate purposes	Not Applicable	INR 170.55/-	NIL/ NA	INR 170.55/-	Not Applicable	-
Total		**INR 1006.00**				

Note:

The Company has raised INR 1161.00 Lakhs by way of Initial Public Offer "IPO" of 27,00,000 Equity shares of Face value of ₹ 10/- each ("equity shares") for cash at a price of INR 43/- per Equity Share (including a share premium of INR 33/- per Equity Share) out of which the Net Proceeds stood at INR 1006.00 Lakhs. The equity shares of the Company got listed with SME Platform of BSE Limited on May 19, 2026. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi

Digitally signed by Ruchi Sanket Modi
Date: 2026.11.14 19:51:42 +05'30'

Ruchi Sanket Modi

Company Secretary cum Compliance Officer

B. SHROFF & Co.
CHARTERED ACCOUNTANTS

CA. Nilesh Tiwari
(Partner) B.SC., FCA, DISA
9970854770
ca.nileshtiwari@gmail.com

Statement on deviation / variation in utilisation of funds raised
Disclosure for utilization of Initial Public Offer ('IPO') issue proceeds for Goldline Pharmaceutical Limited as on 30th September, 2026

To,
Goldline Pharmaceutical Limited,
103, F1, Leela Apartment, Near Shanidham,
Shilpa Society, Saptagiri Nagar,
Nagpur, Maharashtra, India - 440015.

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc.	
Name of listed entity	Goldline Pharmaceutical Limited
Mode of Fund Raising	Public Issue - Initial Public Offer ('IPO')
Date of Raising Funds	May 19, 2026
Amount Raised	INR 10,06,00,000/-
Report filed for Quarter ended	September 30, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	NA
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	The Audit Committee has reviewed that there was no deviation/variation in the use of funds raised through Preferential Issue.
Comments of the auditors, if any	NIL

B SHROFF & CO. NAGPUR CHARTERED ACCOUNTS

B. SHROFF & Co.
CHARTERED ACCOUNTANTS

CA. Nilesh Tiwari
(Partner) B.SC., FCA, DISA
9970854770
ca.nileshtiwari@gmail.com

Objects for which funds have been raised and where there has been a deviation, in the following table:

Original Object	Modified Object, if any	Original Allocation (in Lakhs)	Modified Allocation, if any	Funds Utilised (in Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if Any
1. Repayment of all or a portion of certain outstanding borrowings availed by our company.	Not Applicable	INR 835.45	NIL/ NA	INR 835.45	Not Applicable	
2. General corporate purposes	Not Applicable	INR 170.55/-	NIL/ NA	INR 170.55/-	Not Applicable	
Total		**INR 1006.00**				

Note:
The Company has raised INR 1161.00 Lakhs by way of Initial Public Offer "IPO" of 27,00,000 Equity shares of Face value of ₹ 10/- each ("equity shares") for cash at a price of INR 43/- per Equity Share (including a share premium of INR 33/- per Equity Share) out of which the Net Proceeds stood at INR 1006.00 Lakhs. The equity shares of the Company got listed with SME Platform of BSE Limited on May 19, 2026. The issue was made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc

For B Shroff & Co,
Chartered Accountants
FRN: 006514W

B SHROFF & CO. NAGPUR CHARTERED ACCOUNTS

CA Nilesh Tiwari
Partner
Membership Number: 130513
UDIN: 26130513FVANEF9176
Place: Nagpur
Dt. 14/11/2026